{"title":"A systematic review and meta-analysis of chondroitinase ABC promotes functional recovery in rat models of spinal cord injury.","authors":"Ya-Yun Zhang, Rui-Rui Xue, Min Yao, Zhuo-Yao Li, Cai-Wei Hu, Yu-Xiang Dai, Yi-de Fang, Xing Ding, Jin-Hai Xu, Xue-Jun Cui, Wen Mo","doi":"10.1080/1028415X.2023.2278867","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To comprehensively assess the neurologic recovery potential of chondroitinase ABC (ChABC) in rats after spinal cord injury (SCI).</p><p><strong>Methods: </strong>The PubMed, Embase, ScienceDirect, Web of Science, and China National Knowledge Infrastructure databases were searched for animal experiments that evaluated the use of ChABC in the treatment of SCI up to November 2022. Studies reporting neurological function using the Basso, Beattie, and Bresnahan (BBB) scale, as well as assessments of cavity area, lesion area, and glial fibrillary acidic protein (GFAP) levels, were included in the analysis.</p><p><strong>Results: </strong>A total of 46 studies were ultimately selected for inclusion. The results of the study showed that rats with SCI that received ChABC therapy exhibited a significant improvement in locomotor function after 7 days compared with controls (32 studies, weighted mean difference (WMD) = 0.58, [0.33, 0.83], <i>p </i>< 0.00001). Furthermore, the benefits of ChABC therapy were maintained for up to 28 days according to BBB scale. The lesion area was reduced by ChABC (5 studies, WMD = -20.94, [-28.42, -13.46], <i>p </i>< 0.00001). Meanwhile, GFAP levels were reduced in the ChABC treatment group (8 studies, WMD = -29.15, [-41.57, -16.72], <i>p < </i>0.00001). Cavity area is not statistically significant. The subgroup analysis recommended that a single injection of 10 μL (8 studies, WMD = 2.82, [1.99, 3.65], <i>p < </i>0.00001) or 20 U/mL (4 studies, WMD = 2.21, [0.73, 3.70], <i>p = </i>0.003) had a better effect on improving the function. The funnel plot of the BBB scale was found to be essentially symmetrical, indicating a low risk of publication bias.</p><p><strong>Conclusions: </strong>This systematic review and meta-analysis has indicated that ChABC could improve functional recovery in rats after SCI.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"917-933"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutritional Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1028415X.2023.2278867","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: To comprehensively assess the neurologic recovery potential of chondroitinase ABC (ChABC) in rats after spinal cord injury (SCI).
Methods: The PubMed, Embase, ScienceDirect, Web of Science, and China National Knowledge Infrastructure databases were searched for animal experiments that evaluated the use of ChABC in the treatment of SCI up to November 2022. Studies reporting neurological function using the Basso, Beattie, and Bresnahan (BBB) scale, as well as assessments of cavity area, lesion area, and glial fibrillary acidic protein (GFAP) levels, were included in the analysis.
Results: A total of 46 studies were ultimately selected for inclusion. The results of the study showed that rats with SCI that received ChABC therapy exhibited a significant improvement in locomotor function after 7 days compared with controls (32 studies, weighted mean difference (WMD) = 0.58, [0.33, 0.83], p < 0.00001). Furthermore, the benefits of ChABC therapy were maintained for up to 28 days according to BBB scale. The lesion area was reduced by ChABC (5 studies, WMD = -20.94, [-28.42, -13.46], p < 0.00001). Meanwhile, GFAP levels were reduced in the ChABC treatment group (8 studies, WMD = -29.15, [-41.57, -16.72], p < 0.00001). Cavity area is not statistically significant. The subgroup analysis recommended that a single injection of 10 μL (8 studies, WMD = 2.82, [1.99, 3.65], p < 0.00001) or 20 U/mL (4 studies, WMD = 2.21, [0.73, 3.70], p = 0.003) had a better effect on improving the function. The funnel plot of the BBB scale was found to be essentially symmetrical, indicating a low risk of publication bias.
Conclusions: This systematic review and meta-analysis has indicated that ChABC could improve functional recovery in rats after SCI.
背景:综合评价大鼠脊髓损伤(SCI)后软骨素酶ABC (ChABC)的神经功能恢复潜力。方法:检索PubMed、Embase、ScienceDirect、Web of Science和中国国家知识基础设施数据库，检索截至2022年11月评估ChABC在SCI治疗中使用的动物实验。使用Basso, Beattie, and Bresnahan (BBB)量表报告神经功能的研究，以及对空洞面积，病变面积和胶质纤维酸性蛋白(GFAP)水平的评估被纳入分析。结果:最终共纳入46项研究。研究结果显示，与对照组相比，接受ChABC治疗的脊髓损伤大鼠在7天后运动功能有显著改善(32项研究，加权平均差(WMD) = 0.58， [0.33, 0.83]， p p p 0.00001)。空腔面积差异无统计学意义。亚组分析提示单次注射10 μL(8项研究，WMD = 2.82， [1.99, 3.65]， p 0.00001)或20 U/mL(4项研究，WMD = 2.21， [0.73, 3.70]， p = 0.003)对功能的改善效果更好。BBB量表的漏斗图基本对称，表明发表偏倚风险较低。结论:本系统综述和荟萃分析表明，ChABC可以改善脊髓损伤后大鼠的功能恢复。
期刊介绍：
Nutritional Neuroscience is an international, interdisciplinary broad-based, online journal for reporting both basic and clinical research in the field of nutrition that relates to the central and peripheral nervous system. Studies may include the role of different components of normal diet (protein, carbohydrate, fat, moderate use of alcohol, etc.), dietary supplements (minerals, vitamins, hormones, herbs, etc.), and food additives (artificial flavours, colours, sweeteners, etc.) on neurochemistry, neurobiology, and behavioural biology of all vertebrate and invertebrate organisms. Ideally this journal will serve as a forum for neuroscientists, nutritionists, neurologists, psychiatrists, and those interested in preventive medicine.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
